Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.

Abstract

Although substantial progress has been made in optimizing the adjuvant treatment of breast cancer, many of the most important proven agents carry a risk for potentially severe toxicity. Taxanes can cause febrile neutropenia and related serious infections, and anthracyclines and trastuzumab are associated with a small risk of clinically significant cardiac toxicity. These adverse events can limit the ability to deliver adjuvant treatment because of needed dose reductions and scheduling delays, which may attenuate the effectiveness of regimens designed to improve survival or cure patients with early-stage breast cancer. A major goal of adjuvant therapy is to maximize efficacy while minimizing severe acute and long-term, treatment-related toxicities. This article discusses therapeutic strategies that can reduce life-threatening cardiac toxicity and febrile neutropenia resulting from adjuvant breast cancer therapy.

Statistics

0200400600800201520162017
Citations per Year

81 Citations

Semantic Scholar estimates that this publication has 81 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{OShaughnessy2007ManagementOF, title={Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.}, author={Joyce O'Shaughnessy}, journal={Clinical breast cancer}, year={2007}, volume={8 Suppl 1}, pages={S11-21} }